Pharmacokinetics of Oral Valganciclovir and Intravenous Ganciclovir Administered to Prevent Cytomegalovirus Disease in an Adult Patient Receiving Small-Intestine Transplantation
- 1 July 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (7) , 2782-3
- https://doi.org/10.1128/aac.48.7.2782-2783.2004
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2000
- Single‐Dose Pharmacokinetics of Valganciclovir in HIV‐ and CMV‐Seropositive SubjectsThe Journal of Clinical Pharmacology, 1999
- HAMSTER TO RAT KIDNEY XENOTRANSPLANTATION EFFECTS OF FK 506, CYCLOPHOSPHAMIDE, ORGAN PERFUSION, AND COMPLEMENT INHIBITIONTransplantation, 1995
- INCIDENCE AND RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF CYTOMEGALOVIRUS DISEASE AFTER INTESTINAL TRANSPLANTATIONTransplantation, 1995